Amarin’s Vascepa prevents second and third heart attacks in analysis, fueling debate
A fish-oil-derived drug sold by Amarin Pharmaceuticals helped prevent not only initial cardiovascular events but also second and third heart attacks, according to a new analysis. #ACC19
NEW ORLEANS — A new analysis of a large study unveiled last November shows that Vascepa, a fish-oil-derived drug sold by Amarin Pharmaceuticals, reduces second and third heart attacks as well as first ones.
The analysis, presented Monday at the annual meeting of the American College of Cardiology here and published in the college’s academic journal, found that Vascepa cut by 30 percent the rate of first and subsequent cardiovascular problems — defined as deaths from heart disease, heart attacks or strokes, procedures such as stenting, or hospitalizations for chest pain — compared to placebo in
